

Claims:

1. A genetically modified non-human mammal or cell characterised in that
5 it does not comprise a nucleic acid sequence which itself encodes any endogenous immunoglobulin heavy chain constant region locus polypeptide.
2. A genetically modified non-human mammal or cell according to claim 1
10 characterised in that it does not comprise a nucleic acid sequence which itself encodes any immunoglobulin heavy chain constant region (IgH C) polypeptide.
3. A genetically modified non-human mammal or cell according to claim 1
or claim 2 characterised in that all immunoglobulin heavy chain constant region
15 gene sequences are absent or partially absent from the genome.
4. A genetically modified non-human mammal or cell according to any of
the preceding claims, characterised in that it is obtainable or obtained by targeted
deletion of essentially all endogenous IgH C gene sequences.
- 20 5. A genetically modified non-human mammal or cell according to any of
the preceding claims characterised in that it is obtainable or obtained by Cre *loxP*
recombination.
- 25 6. A genetically modified non-human mammal or cell according to any of
the preceding claims characterised in that at least part of at least one IgH C gene
enhancer sequence is present.
- 30 7. A genetically modified non-human mammal or cell according to any of
the preceding claims characterised in that a non-endogenous site-specific
recombination sequence is present within the genome.

8. A genetically modified non-human mammal or cell characterised by having a non-endogenous site-specific recombination sequence downstream of, or within the last gene of the IgH C locus.

5 9. A genetically modified non-human mammal or cell according to claim 8 characterised by having a further non-endogenous site specific recombination sequence upstream of, or within the first gene of the IgH C locus.

10 10. A genetically modified non-human mammal or cell according to any of the preceding claims characterised in that one or more endogenous Ig H variable region, D and/or J segment nucleic acid sequences are present.

15 11. A genetically modified non-human mammal or cell according to any of the preceding claims characterised in that one or more selectable marker(s) is present within the genome.

20 12. A genetically modified non-human mammal or cell according to claim 8 characterised in that at least one selectable marker is present upstream of, or downstream of, the non-endogenous site specific recombination sequence.

25 13. A genetically modified non-human mammal or cell according to claim 9 characterised in that at least one selectable marker is integrated within the genome upstream of, and/or downstream of, at least one non-endogenous site specific recombination sequence.

30 14. A genetically modified non-human mammal or cell according to any of claims 11 to 13 characterised in that the selectable marker(s) is one or more selectable marker selected from a group comprising a neomycin resistance gene, a puromycin resistance gene, and a hygromycin resistance gene.

15. A genetically modified non-human mammal or cell according to any of claims 7 to 14 characterised in that the non-endogenous site-specific recombination sequence is a *loxP* site.

5 16. A genetically modified non-human mammal according to any of the preceding claims characterised in that it is a mouse.

17. A genetically modified non-human cell according to any of claims 1 to 15 characterised in that it is a mouse cell.

10

18. A genetically modified mouse according to claim 16, or a genetically modified mouse cell according to claim 17, characterised in that all eight endogenous IgH C genes μ , δ , $\gamma 3$, $\gamma 1$, $\gamma 2a$, $\gamma 2b$, ϵ and α are absent or partially absent.

15

19. A genetically modified non-human cell according to any of claims 1 to 15 or claim 17 or 18 characterised in that it is an embryonic stem cell.

20. A genetically modified non-human mammal derived from a genetically modified non-human mammal of any of claims 1 to 16 or claim 18.

20

21. A genetically modified non-human mammal derived from a genetically modified non-human cell of any of claims 1 to 15 or any of claims 17 to 19.

22. A genetically modified non-human cell derived from a genetically modified non-human mammal of any of claims 1 to 16 or claim 18.

25

23. A method for producing a genetically modified non-human cell comprising:

30 (a) (i) transfecting a non-human cell with a targeting construct for integration upstream of, or within the first IgH C gene of the IgH C locus, said targeting construct comprising a non-endogenous site specific

recombination sequence and a selectable marker, selecting for a cell in which the selectable marker is present and screening said cell for integration of the recombination sequence, and,

5 (ii) transfecting a cell produced in (a)(i) with a targeting construct for integration downstream of, or within the last IgH C gene of the IgH C locus, said targeting construct comprising a selectable marker and a non-endogenous site-specific recombination sequence, selecting for a cell in which the selectable marker is present and screening said cell for integration of the recombination sequence; or

10 (b) (i) transfecting a non-human cell with a targeting construct for integration downstream of, or within the last IgH C gene of the IgH C locus, said targeting construct comprising a non-endogenous site-specific recombination sequence and a selectable marker selecting for a cell in which the selectable marker is present, and screening said cell for integration of the recombination sequence, and

15 (ii) transfecting a cell produced in (b)(i) with a targeting construct for integration upstream of, or within the first IgH C gene of the IgH C locus, said targeting construct comprising a non-endogenous site-specific recombination sequence and a selectable marker, selecting for a cell in which the selectable marker is present, and screening said cell for integration of the recombination sequence; or

20 (c) co-transfecting a non-human cell with a targeting construct for integration upstream of, or within the first IgH C gene of the IgH C locus and with a targeting construct for integration downstream of, or within the last IgH C gene of the IgH C locus, each of said targeting constructs comprising a non-endogenous site specific recombination sequence and each having a selectable marker, selecting for a cell in which the selectable marker(s) is/are present, and screening said cell for integration of the recombination sequence; and optionally,

25 (d) providing to a cell obtained in (a)(ii), (b)(ii) or (c) a recombinase active at the non-endogenous site-specific recombination sequence and, optionally, screening for deletion events.

24. A method according to claim 23 characterised in that the non-endogenous site-specific recombination sequence is a *loxP* site.

5 25. A method according to claim 24 characterised in that, in optional step (d), the recombinase is a Cre recombinase.

26. A method according to any of claims 23 to claim 25 characterised in that the recombinase is provided by an expression vector.

10

27. A method according to any of claims 23 to 26 characterised in that the genetically modified non-human cell is a mouse cell.

15

28. A method according to any of claims 23 to 27 characterised in that the genetically modified non-human cell is an embryonic stem cell.

20

29. The use of an embryonic stem cell of claim 19 or a cell obtainable by a method of any of claims 23 to 28 for the production of a genetically modified non-human mammal.

25

30. A method for producing a genetically modified non-human mammal characterised in that an embryonic stem cell of claim 19 or obtainable by a method of claim 28 is introduced into a host blastocyst and developed into a chimaeric animal.

30

31. A method according to claim 30 characterised by:
(a) introducing a non-human mammal embryonic stem cell according to claim 19 or obtainable by a method of claim 28 into a compatible non-human mammal blastocyst, and
(b) transplanting the blastocyst obtained in (a) into a compatible non-human mammal foster mother to obtain a chimaeric non-human mammal, and optionally, screening for the selectable marker(s), and/or the non-

endogenous site specific recombination sequence(s), and/or for deletion of essentially all endogenous IgH C gene sequences.

5 32. A method for producing a genetically modified non-human mammal characterised in that the chimaeric non-human mammal according to claim 30 or claim 31 is bred to obtain heterozygous progeny.

10 33. A method for producing a genetically modified non-human mammal characterised in that the heterozygous progeny of claim 32 is inter-bred to obtain homozygous progeny.

15 34. A method for producing a genetically modified non-human mammal characterised by cross-breeding a genetically modified non-human mammal homozygous for integration of a non-endogenous site-specific recombination sequence upstream of, or within the first IgH C gene of the IgH C locus with a compatible genetically modified non-human mammal homozygous for integration of a non-endogenous site-specific recombination sequence downstream, or within the last IgH C gene of the IgH C locus, to obtain heterozygous progeny and optionally interbreeding the heterozygous progeny to obtain progeny homozygous for both integrations.

20

25 35. A method according to claim 34 characterised by further comprising cross-breeding progeny homozygous for both integrations with a compatible non-human mammal capable of expressing a recombinase active at the non-endogenous site specific recombination sequence to obtain progeny; and optionally screening the progeny obtained for IgH C gene deletion.

30 36. A method according to claim 34 or claim 35 characterised in that the non-endogenous site specific recombination sequence(s) are *loxP* sites.

37. A method according to claim 36 characterised in that the recombinase is a Cre recombinase.

38. A method according to claim 36 characterised by further comprising cross-breeding progeny heterozygous or homozygous for *loxP* at both loci with a compatible non-human mammal capable of expressing Cre recombinase to obtain a progeny non-human mammal that does not comprise a nucleic acid sequence which itself encodes any endogenous Ig heavy chain constant region polypeptide on one or both alleles.

39. A genetically modified non-human mammal characterised in that it is obtainable or obtained by a method of claim 35 to claim 38 and does not comprise a nucleic acid sequence which itself encodes any endogenous Ig heavy chain constant region polypeptide.

40. A method for producing a genetically modified non-human mammal capable of expressing one or more exogenous genes, characterised by breeding a genetically modified non-human mammal according to claims 1 to 7 or claims 10 to 16 or claims 18 to 21 that does not comprise a nucleic acid sequence which itself encodes any endogenous immunoglobulin heavy chain constant region polypeptide, with a compatible non-human mammal that encodes and is capable of expressing one or more exogenous gene(s), to obtain progeny heterozygous for the one or more exogenous gene(s), and optionally inter-breeding the heterozygous progeny to produce progeny homozygous for the one or more exogenous gene(s).

41. A method for producing a genetically modified non-human mammal or cell capable of expressing one or more exogenous gene(s) characterised by comprising introduction of one or more exogenous gene(s) into a non-human mammalian cell according to claims 1 to 7 or claims 10 to 15 or claims 17 to 21 that does not comprise a nucleic acid sequence which itself encodes any endogenous immunoglobulin heavy chain constant region polypeptide.

42. A method according to claim 41 characterised in that the non-human mammalian cell is an embryonic stem cell.

43. A method according to claim 42, characterised in that the one or more exogenous gene(s) are introduced by transfection.

5 44. A method according to claim 41 characterised in that the non-human mammal cell is an oocyte (egg cell).

45. A method according to claim 44, characterised in that the one or more exogenous gene(s) are introduced by DNA micro-injection.

10

46. A method according to any of claims 41 to 45 characterised in that the one or more exogenous gene(s) are inserted into the genome of the non-human mammal or cell.

15

47. A method according to claim 46 characterised in that the one or more exogenous gene(s) are inserted into a non-endogenous site specific recombination sequence.

20

48. A method for producing a genetically modified non-human mammal capable of expressing one or more exogenous gene(s) characterised by cross-breeding a non-human mammal that does not comprise a nucleic acid sequence which itself encodes any endogenous immunoglobulin heavy chain constant region polypeptide with a transgenic mammal having one or more exogenous gene(s) associated with or flanked by a non-endogenous site specific recombination sequence and having a recombinase active at the non-endogenous site specific recombination sequence to obtain progeny and optionally screening the progeny for insertion of the one or more exogenous gene(s).

25

49. A method according to any of claims 46 to 48 characterised in that the non-endogenous site specific recombination sequence is a *loxP* sequence and insertion is by Cre – *lox P* integration.

30

50. A method according to any of claims 40 to 49 characterised in that the genetically modified non-human mammal is a mouse.

5 51. A method according to any of claims 40 to 50 characterised in that the exogenous gene or genes is an Ig H gene or Ig H genes.

52. A method according to claim 51 characterised in that the Ig H gene or genes is an IgH C gene or IgH C genes.

10 53. A method according to any of claims 40 to 52 characterised in that the exogenous genes or genes are a human gene or human genes.

15 54. A method according to any one of claims 40 to 53 characterised in that the exogenous genes are a human Ig heavy chain locus having V, D, J and/or C regions.

55. A method according to claim 54 wherein the human Ig heavy chain locus V, D, J and/or C regions are in germline configuration.

20 56. A method according to claim 54 wherein the human Ig heavy chain locus V, D, J and/or C regions are productively arranged.

25 57. A non-human mammal or cell obtainable by a method of any of claims 40 to 56.

58. The use of a non-human mammal or cell according to claim 57 in the production of an exogenous immunoglobulin.

30 59. The use of a non-human mammal or cell according to claim 57 in the production of a human immunoglobulin.

60. A method for production of exogenous immunoglobulin comprising use of a non-human mammal or cell according to claim 57.
- 5 61. A method for production of human immunoglobulin comprising use of a non-human mammal or cell according to claim 57.
62. A method or use according to any one of claims 58 to 61 wherein the non-human mammal is a rodent.
- 10 63. A method or use according to any one of claims 58 to 61 wherein the non-human mammal is a mouse.
64. A method or use according to any one of claims 58 to 61 wherein the non-human cell is a rodent cell.
- 15 65. A method or use according to any one of claims 58 to 61 wherein the non-human cell is a mouse cell.
66. An immunoglobulin obtainable or obtained by a method according to any one of claims 60 to 65.
- 20 67. A human immunoglobulin obtainable or obtained by a method according to any one of claims 60 to 65.
- 25 68. An immunoglobulin according to claim 66 or claim 67 for use as a medicament.
69. The use of an immunoglobulin according to claim 66 or claim 67 in the manufacture of a medicament.
- 30 70. A medicament composition comprising an immunoglobulin according to claim 66 or claim 67 and a pharmaceutically acceptable excipient.